Medical AMPersonalized Medicine

CurifyLabs launches 3D printable Pharma Inks

Making the company one of the first to offer the 3D printing of medicine as a scalable and practical service for producing patient-tailored and personalized medicines in pharmacies and hospitals

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

CurifyLabs, a Finnish healthtech company, has launched its GMP (good manufacturing practice) produced Pharma Inks for 3D printable medicines – making it one of the first companies to offer the 3D printing of medicine as a scalable and practical service. The inks provide a novel solution for producing patient-tailored and personalized medicines in pharmacies and hospitals. CurifyLabs’ Pharma Kit, including automated 3D printing technology combined and printable pharmaceutical inks, enables the wider adoption of personalized medicine – resulting in better future care for patients with different needs.

The demand for personalized medicine is increasing. Genetic differences, age, gender, allergies, and disabilities can all affect how individuals react to the medication. The mass production of medicine and standardized dosages can lead to ineffective treatment, side effects, and significant health risks for certain patients. Personalized treatment and medication are crucial, especially for patients in vulnerable situations like cancer patients and children. According to a report by the European Commission, over 50% of medicines are not currently registered for use in children. Moreover, there is increasing evidence that pharmacogenetic testing in the optimization of drug dosing reduces adverse reactions in patients.

“There is a significant need for scalable and practical methods to produce customized drugs that precisely match a patient’s needs. We are thrilled to introduce the world’s first Pharma Ink for 3D printing of drugs and offer a solution for producing personalized medicines in pharmacies and hospitals efficiently and safely. This enables wider drug availability and better care for people with various medical conditions, particularly those in vulnerable situations where personalized treatment is the only option,” said Charlotta Topelius, CEO and Co-founder of CurifyLabs.

Currently, compounding (the preparation of personalized drug treatments) is done manually in pharmacies. Pharmacists measure and mix different ingredients to create medications tailored to specific patient requirements. While this practice ensures customization, it often comes at the cost of time and potential human errors – compromising efficiency and patient safety.

CurifyLabs launches 3D printable Pharma Inks - offering personalized medicines in pharmacies and hospitals.

To address the operational, financial, regulatory, and clinical challenges hindering the wider adoption of personalized medicines, CurifyLabs has developed an automated on-demand manufacturing concept – the CurifyLabs Pharma Kit – allowing for the production of personalized medicines, onsite, in pharmacies. CurifyLabs’ team of pharmacists has developed a variety of printable pharmaceutical inks, for a wide range of APIs that are commonly compounded in pharmacies today. With CurifyLabs Pharma Printer and Pharma Inks, pharmacists have access to a library of printable inks for fast 3D printing in compliance with regulatory requirements for the field.

“Pharmacy-tailored drug manufacturing is very laborious and involves manual work steps. We have been waiting for this type of technology”, said Catharina Kern, a Pharmacist at Münster University Hospital.

“Pharmaceutical 3D printing automates the time-consuming manual compounding process, enabling pharmacists to efficiently produce custom medications while maintaining high manufacturing standards. The quality of all drugs produced are verified with in-process quality control tools with our solution. Our technology can save up to 70% of the time compared to manual methods,” said Niklas Sandler, CTO and Founder of CurifyLabs.

Making high-quality automated compounding accessible to all pharmacies and patients unlocks a unique opportunity in a rapidly growing market. According to Global Market Insights, the global compounding market was valued at $11 billion in 2022, and it is projected to reach $18.2 billion by 2030 – driven by the increasing demand for personalized medication.

“With our 3D printing solutions, we aim to reshape the landscape of pharmacy-tailored medicines in hospital and compounding pharmacies. Our goal is to build foundations for a healthcare system that delivers not only customized medications but also greater convenience, enhanced patient safety, and time savings for pharmacists”, said Charlotta Topelius.

Research
Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Edward Wakefield

Edward is a freelance writer and additive manufacturing enthusiast looking to make AM more accessible and understandable.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Save
Accept all Services

Newsletter

Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.